Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Laura J. Esserman, MD, of the University of California, San Francisco, explains how to improve breast cancer screening practices.
University of Colorado’s Jennifer Diamond, MD, talks about how clinical trials work in breast cancer and what they can do for patients.
As a family medicine physician and a breast cancer patient, Cheryl Law shares how she navigates her own treatment.
Dana-Farber breast cancer researchers performed genomic testing, yielding findings may help personalize treatment in the future.
Check out these promising breast cancer studies.
This treatment represents a “fairly substantial breakthrough” for patients with HER2-positive advanced colorectal cancer.
Patients treated with Trodelvy had a 21% reduction in the risk for death.
Research also showed that treatment before surgery benefits patients with HER2-low breast cancer.
The results could also be relevant for people with other types of HER2-low cancer.
The antibody-drug conjugate improved progression-free and overall survival for patients with low HER2 expression on breast tumors.
Researchers at Dana-Farber Cancer Institute show that “HER2-low” tumors are not a distinct subtype of breast cancer.
Artificial intelligence and machine learning can help identify genetic changes that lead to cancer—and which treatments work best.
The new cancer subtypes help better characterize a person’s tumor. The goal is to get the right drug to the right patient.
A look at the symptoms, treatments, risk factors, prognosis and research on breast cancer metastasis to the brain.
Here are latest cancer drugs approved by the Food and Drug Administration.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.